BusinessPoseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual MeetingBy Nasdaq OMXApr 4, 2017, 12:01 PM UTC
BusinessPoseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual MeetingBy Nasdaq OMXApr 4, 2017, 12:01 PM UTC
BusinessPoseida Therapeutics Appoints Debra Gessner as Vice President, Regulatory AffairsBy Nasdaq OMXJan 3, 2017, 2:00 PM UTC
BusinessPoseida Therapeutics to Present Three Abstracts on Novel BCMA-Specific CAR-T Therapy at American Society of Hematology 2016 Annual MeetingBy Nasdaq OMXNov 3, 2016, 1:00 PM UTC
BusinessPoseida Therapeutics Establishes Scientific Advisory BoardBy Nasdaq OMXSep 8, 2016, 11:30 AM UTC
